Sorry! Your browser is not supported.
To view this site you can download a newer version of .
Mesynthes was founded in Wellington in 2007, developing a new type of tissue sheet for wound care and surgery. Its founder is Brian Ward, a former veterinarian and head of NZBio. He began developing a regenerative wound care product derived from sheep forestomach - taking a particular layer of that tissue and treating it so that it encourages tissue regeneration and the human body does not react to it
In 2010, it gained US Food and Drug Administration 510k clearance for its product’s commercial launch into the lucrative US health market.
It is a replacement for the traditional surgical technique of cutting and pasting human tissue from another site. Using animal tissue has the benefit of being quick, leaving only one wound site to deal with.
The company has raised investment from a range of New Zealand investors including Movac, Sparkbox, K1W1, CureKid Ventures, as well as NZVIF.
In 2010, it gained US Food and Drug Administration 510k clearance for its product’s commercial launch into the lucrative US health market.
It is positioning itself as a medical device company, having developed foundation material which can be used in devices to repair abdominal walls, hernias, cardiovascular tissue, tendons, and virtually any soft tissue requiring structural repair.
